Aeon Biopharma Inc (AEON)

$0.79 -0.05 (-5.48%)
Market Cap 9.47M
Revenue (ttm) 0.00
Net Income (ttm) 42.01M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 204,389
Avg Vol 971,368
Day's Range N/A - N/A
Shares Out 11.31M
Stochastic %K 69%
Beta 0.71
Analysts Strong Sell
Price Target $359.71

Company Profile

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder. The company has license agreements Daewoong Pharmaceu...

Industry: Biotechnology
Sector: Healthcare
Phone: 949 354 6499
Address:
5 Park Plaza, Suite 1750, Irvine, United States
ka1954
ka1954 Jul. 7 at 7:32 PM
$AEON u guys DO know that u don't have to sell just because indexes is selling. i just thought i shud tell u guys in case u forgot. LOL
0 · Reply
VinWeezel
VinWeezel Jul. 7 at 12:55 PM
$AEON
0 · Reply
Moonster25
Moonster25 Jul. 3 at 2:38 PM
$AEON Lol, always loses its gains
0 · Reply
Mandi63
Mandi63 Jul. 3 at 1:18 PM
$AEON POTENTIALLY EABLE A SINGLE FDA APPROVAL COVERING ALL BOTOX’S CURRENT AND FUTURE THERAPEUTIC INDICATIONS..
0 · Reply
Mandi63
Mandi63 Jul. 3 at 1:12 PM
$AEON Bullish…LETS GO… $1.00 PLUS…
0 · Reply
Moonster25
Moonster25 Jul. 2 at 5:42 PM
$AEON Told ya
1 · Reply
Mandi63
Mandi63 Jul. 2 at 3:42 PM
$AEON NO BRAINER …LOOKING FOR AMAZING RESULTS TO BE ANNOUNCED WITH FDA … INSIDE BUYING CEO WITH 25 YEARS EXPERIENCE ECT… AVERAGE HOLDERS ABOVE $10.00-25.00 LOW FLOAT LOOK FOR ABOVE $1.00
1 · Reply
Moonster25
Moonster25 Jul. 2 at 1:01 PM
$AEON So far my prediction is accurate,
0 · Reply
Mandi63
Mandi63 Jul. 2 at 8:13 AM
$AEON $EOLS
0 · Reply
Moonster25
Moonster25 Jul. 1 at 9:13 PM
$AEON This won't be up 10% tomorrow , guarantee it
1 · Reply
Latest News on AEON
AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711

May 23, 2025, 4:05 PM EDT - 6 weeks ago

AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711

AEON Biopharma to Present at the Aegis Capital Corp. Virtual Conference 2025

May 19, 2025, 4:05 PM EDT - 7 weeks ago

AEON Biopharma to Present at the Aegis Capital Corp. Virtual Conference 2025

AEON Biopharma Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 14, 2025, 4:05 PM EDT - 7 weeks ago

AEON Biopharma Reports First Quarter 2025 Financial Results and Provides Corporate Update

AEON Biopharma Announces NYSE American Acceptance of Plan to Regain Listing Compliance

Apr 25, 2025, 4:05 PM EDT - 2 months ago

AEON Biopharma Announces NYSE American Acceptance of Plan to Regain Listing Compliance

AEON Biopharma Appoints Industry Veteran Rob Bancroft as Chief Executive Officer

Apr 21, 2025, 4:05 PM EDT - 2 months ago

AEON Biopharma Appoints Industry Veteran Rob Bancroft as Chief Executive Officer

AEON Biopharma Announces CEO Transition

Mar 27, 2025, 4:05 PM EDT - 3 months ago

AEON Biopharma Announces CEO Transition

AEON Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Mar 24, 2025, 4:05 PM EDT - 3 months ago

AEON Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

AEON Biopharma, Inc. to Participate in the Leerink Global Healthcare Conference

Mar 4, 2025, 8:00 AM EST - 4 months ago

AEON Biopharma, Inc. to Participate in the Leerink Global Healthcare Conference

AEON Biopharma, Inc. Announces Reverse Stock Split

Feb 24, 2025, 2:00 PM EST - 4 months ago

AEON Biopharma, Inc. Announces Reverse Stock Split

AEON Biopharma, Inc. Receives Notice of Non-Compliance with NYSE American Continued Listing Standards

Feb 7, 2025, 4:05 PM EST - 5 months ago

AEON Biopharma, Inc. Receives Notice of Non-Compliance with NYSE American Continued Listing Standards

AEON Biopharma, Inc. Announces Closing of $20.0 Million Underwritten Public Offering

Jan 7, 2025, 9:37 AM EST - 6 months ago

AEON Biopharma, Inc. Announces Closing of $20.0 Million Underwritten Public Offering

AEON Biopharma, Inc. Announces Launch of Proposed Public Offering

Jan 3, 2025, 8:02 PM EST - 6 months ago

AEON Biopharma, Inc. Announces Launch of Proposed Public Offering

AEON Biopharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 13, 2024, 4:05 PM EST - 8 months ago

AEON Biopharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update

AEON Biopharma to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024

Aug 19, 2024, 4:05 PM EDT - 11 months ago

AEON Biopharma to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024

AEON Biopharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 12, 2024, 4:05 PM EDT - 11 months ago

AEON Biopharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update

AEON Biopharma Announces Strategic Resource Reprioritization and Cost Reduction Plan

May 29, 2024, 8:00 AM EDT - 1 year ago

AEON Biopharma Announces Strategic Resource Reprioritization and Cost Reduction Plan

AEON Biopharma Reports First Quarter 2024 Financial Results

May 14, 2024, 4:05 PM EDT - 1 year ago

AEON Biopharma Reports First Quarter 2024 Financial Results

AEON Biopharma Provides Update on Development Pipeline

May 9, 2024, 8:00 AM EDT - 1 year ago

AEON Biopharma Provides Update on Development Pipeline

AEON Biopharma Announces Preliminary Top-Line Results from Phase 2 Interim Analysis of ABP-450 in the Preventive Treatment of Chronic Migraine

May 3, 2024, 7:00 AM EDT - 1 year ago

AEON Biopharma Announces Preliminary Top-Line Results from Phase 2 Interim Analysis of ABP-450 in the Preventive Treatment of Chronic Migraine

CORRECTION -- AEON Biopharma Announces Redemption of Public Warrants

Mar 30, 2024, 10:53 PM EDT - 1 year ago

CORRECTION -- AEON Biopharma Announces Redemption of Public Warrants

AEON Biopharma Announces Redemption of Public Warrants

Mar 29, 2024, 4:15 PM EDT - 1 year ago

AEON Biopharma Announces Redemption of Public Warrants

AEON Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results

Mar 29, 2024, 3:45 PM EDT - 1 year ago

AEON Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results

AEON Biopharma Announces Clinical Update and Productive End-of-Phase 2 Meeting with FDA on ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Migraine

Mar 19, 2024, 4:30 PM EDT - 1 year ago

AEON Biopharma Announces Clinical Update and Productive End-of-Phase 2 Meeting with FDA on ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Migraine

AEON Biopharma Announces $15 Million Financing Transaction and Termination of Forward Purchase Agreements

Mar 19, 2024, 4:29 PM EDT - 1 year ago

AEON Biopharma Announces $15 Million Financing Transaction and Termination of Forward Purchase Agreements

AEON Biopharma Presents Positive Clinical and Pre-clinical Data for ABP-450 (prabotulinumtoxinA) in Treating Cervical Dystonia and PTSD, Respectively, at a Leading Neurotoxin Conference

Jan 18, 2024, 4:05 PM EST - 1 year ago

AEON Biopharma Presents Positive Clinical and Pre-clinical Data for ABP-450 (prabotulinumtoxinA) in Treating Cervical Dystonia and PTSD, Respectively, at a Leading Neurotoxin Conference

AEON Biopharma Completes Enrollment in Phase 2 Study of ABP-450 (prabotulinumtoxinA) for Preventive Treatment of Chronic Migraine

Dec 12, 2023, 8:00 AM EST - 1 year ago

AEON Biopharma Completes Enrollment in Phase 2 Study of ABP-450 (prabotulinumtoxinA) for Preventive Treatment of Chronic Migraine

AEON Biopharma Reports Third Quarter 2023 Financial Results

Nov 13, 2023, 8:15 AM EST - 1 year ago

AEON Biopharma Reports Third Quarter 2023 Financial Results

AEON Biopharma Announces Topline Results from Phase 2 Trial of ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Episodic Migraine

Oct 19, 2023, 4:05 PM EDT - 1 year ago

AEON Biopharma Announces Topline Results from Phase 2 Trial of ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Episodic Migraine

AEON Biopharma Presents Positive Results from Phase 2 Clinical Trial of ABP-450 (prabotulinumtoxinA) in Cervical Dystonia at the International Parkinson and Movement Disorders Society Congress®

Aug 29, 2023, 8:00 AM EDT - 2 years ago

AEON Biopharma Presents Positive Results from Phase 2 Clinical Trial of ABP-450 (prabotulinumtoxinA) in Cervical Dystonia at the International Parkinson and Movement Disorders Society Congress®

AEON Biopharma Receives Notice of Allowance from USPTO for a Patent Covering Use of Botulinum Toxins to Treat Migraine Headache

Aug 24, 2023, 8:00 AM EDT - 2 years ago

AEON Biopharma Receives Notice of Allowance from USPTO for a Patent Covering Use of Botulinum Toxins to Treat Migraine Headache

Strathspey Crown Holdings Group, LLC Provides Clarifying Statement Regarding Form 4 Filing with SEC for Holdings in AEON Biopharma

Aug 16, 2023, 7:00 AM EDT - 2 years ago

Strathspey Crown Holdings Group, LLC Provides Clarifying Statement Regarding Form 4 Filing with SEC for Holdings in AEON Biopharma

AEON Biopharma Announces Closing of Business Combination with Priveterra Acquisition Corp. and Provides Pipeline Update

Jul 24, 2023, 7:00 AM EDT - 2 years ago

AEON Biopharma Announces Closing of Business Combination with Priveterra Acquisition Corp. and Provides Pipeline Update

ka1954
ka1954 Jul. 7 at 7:32 PM
$AEON u guys DO know that u don't have to sell just because indexes is selling. i just thought i shud tell u guys in case u forgot. LOL
0 · Reply
VinWeezel
VinWeezel Jul. 7 at 12:55 PM
$AEON
0 · Reply
Moonster25
Moonster25 Jul. 3 at 2:38 PM
$AEON Lol, always loses its gains
0 · Reply
Mandi63
Mandi63 Jul. 3 at 1:18 PM
$AEON POTENTIALLY EABLE A SINGLE FDA APPROVAL COVERING ALL BOTOX’S CURRENT AND FUTURE THERAPEUTIC INDICATIONS..
0 · Reply
Mandi63
Mandi63 Jul. 3 at 1:12 PM
$AEON Bullish…LETS GO… $1.00 PLUS…
0 · Reply
Moonster25
Moonster25 Jul. 2 at 5:42 PM
$AEON Told ya
1 · Reply
Mandi63
Mandi63 Jul. 2 at 3:42 PM
$AEON NO BRAINER …LOOKING FOR AMAZING RESULTS TO BE ANNOUNCED WITH FDA … INSIDE BUYING CEO WITH 25 YEARS EXPERIENCE ECT… AVERAGE HOLDERS ABOVE $10.00-25.00 LOW FLOAT LOOK FOR ABOVE $1.00
1 · Reply
Moonster25
Moonster25 Jul. 2 at 1:01 PM
$AEON So far my prediction is accurate,
0 · Reply
Mandi63
Mandi63 Jul. 2 at 8:13 AM
$AEON $EOLS
0 · Reply
Moonster25
Moonster25 Jul. 1 at 9:13 PM
$AEON This won't be up 10% tomorrow , guarantee it
1 · Reply
Olena
Olena Jul. 1 at 8:37 PM
$AEON Biopharma (NYSE: AEON) reported its Q1 2025 financial results and corporate updates. The company is advancing ABP-450 development through a 351(k) biosimilar regulatory pathway, using BOTOX as the reference product. This pathway could potentially enable a single FDA approval covering all of BOTOX's current and future therapeutic indications. AEON appointed Rob Bancroft as President and CEO, who brings 25+ years of life sciences experience. The company reported $10.4 million in cash as of March 31, 2025, expected to fund operations through Q4 2025. AEON received NYSE American's acceptance of its compliance plan, with a deadline until August 2026 to meet listing standards. The company is preparing for a Biosimilar BPD Type 2a meeting with FDA in H2 2025, targeting the $3.3 billion worldwide therapeutic toxin market.
0 · Reply
Olena
Olena Jul. 1 at 8:20 PM
$AEON no news yet but scheduled for h2.
0 · Reply
ka1954
ka1954 Jul. 1 at 8:06 PM
$AEON well, i hope u guys listened
1 · Reply
Olena
Olena Jul. 1 at 8:00 PM
$AEON something is happening!
0 · Reply
kwongaram
kwongaram Jul. 1 at 3:32 PM
$AEON How long do you keep the house warm?
0 · Reply
Olena
Olena Jul. 1 at 2:41 PM
$AEON enough cash through q4 2025. Few catalysts in H2. Insider bought in May. They will pump it up before raising more cash.
0 · Reply
Mandi63
Mandi63 Jul. 1 at 1:59 PM
$AEON LOW VOLUME CAN WALK IT UP….MAKE THEM PAY MORE…$1.00
0 · Reply
Mandi63
Mandi63 Jun. 30 at 2:09 PM
$AEON I set mine at $10.00 just in case….buyout…ect NEWS PENDING…
1 · Reply
ka1954
ka1954 Jun. 30 at 1:22 PM
$AEON another stock which did shelf offering couple of weeks ago and now got news for a rally, MNTS. i am seeing this pattern now. Company announces shelf offering, stock goes down a little then news comes sometime in the future and stock pops, because in order for them to dilute millions of shares, they need to rally the stock
0 · Reply
kwongaram
kwongaram Jun. 30 at 7:56 AM
$AEON The FDA meeting schedule and comparative analysis study data will be released at 2h, but it is likely late July or August. Early July is unlikely.
1 · Reply
Olena
Olena Jun. 29 at 1:06 AM
$AEON they only have enough cash through q4 2025. What is expectation here? They have to get money somewhere. Pump and offering?
0 · Reply
Olena
Olena Jun. 28 at 7:46 PM
$AEON RS was in February. Since then it is staying under $1 and no major news. Insiders just bought. So may be they are awaiting news very soon. Low float.
0 · Reply